Recombinant Escherichia coli Probable phosphatidylethanolamine transferase Mcr-1 (mcr1)-VLPs

What is MCR-1 and what is its primary function in bacterial cells?

MCR-1 is a plasmid-encoded phosphoethanolamine transferase enzyme that catalyzes the transfer of phosphoethanolamine (PEA) from phosphatidylethanolamine to the lipid A component of bacterial lipopolysaccharide. This modification neutralizes the negative charge of lipid A, thereby reducing the binding affinity of positively charged polymyxin antibiotics like colistin and polymyxin B. MCR-1 was first identified in animal-derived Escherichia coli in 2015 and has since been found in various Enterobacteriaceae strains from human, animal, and environmental sources, raising significant global health concerns as it confers resistance to last-resort antibiotics .

The primary function of MCR-1 is to modify bacterial cell surface structures to enhance survival under antibiotic pressure. The enzyme is membrane-bound and requires zinc ions (Zn²⁺) for its catalytic activity, which occurs through a two-step reaction mechanism .

How do virus-like particles differ from actual viruses, and what makes them useful research tools?

Virus-like particles (VLPs) are self-assembling protein structures that mimic the organization and conformation of native viruses but lack viral genetic material, rendering them non-infectious. VLPs retain the structural properties of virions while functioning as "empty shells" .

VLPs are valuable research tools because they:

• Maintain authentic viral epitope presentation in a highly organized, repetitive manner

• Can be produced in various expression systems (bacterial, yeast, insect, mammalian, and plant)

• Can be engineered to display heterologous antigens or encapsulate various cargo molecules

• Stimulate strong innate and adaptive immune responses through multiple pathways:

  • Activating pattern recognition receptors (PRRs) and Toll-like receptors (TLRs)

  • Inducing strong humoral responses, including T-cell independent IgM production

  • Enhancing antigen uptake, processing, and presentation by antigen-presenting cells via both MHC class I and II pathways

Their small diameter (typically 20-200 nm) facilitates direct drainage to lymph nodes, promoting efficient interactions with immune cells and making them excellent platforms for vaccine development and drug delivery .

What are the optimal expression systems for producing recombinant MCR-1 in E. coli?

For optimal expression of recombinant MCR-1 in E. coli, researchers should consider several methodological approaches:

Expression System Selection:

• E. coli BL21(DE3) is commonly used due to its reduced protease activity and compatibility with T7 promoter-based expression systems

• Low-copy number vectors are recommended as high-level MCR-1 expression can be toxic to host cells, consistent with findings that "over-high expression of mcr-1 cannot be tolerated"

Expression Optimization:

• Use inducible promoters with titratable expression systems (e.g., T7-lac, arabinose, or tetracycline-responsive promoters)

• Grow cultures at lower temperatures (16-25°C) after induction to enhance proper protein folding

• Include appropriate concentrations of Zn²⁺ (typically 0.1-0.5 mM ZnSO₄) in growth media to ensure proper metallation of MCR-1

• Consider fusion tags that enhance solubility (e.g., MBP, SUMO) with precise protease cleavage sites

Research has demonstrated that constitutive expression of MCR-1 at different levels affects both resistance profiles and bacterial fitness. Studies have developed E. coli strains with chromosomally-integrated mcr-1 under promoters of varying strengths, achieving more than 200-fold differences in transcriptional expression . This approach enables systematic investigation of the relationship between MCR-1 expression levels and phenotypic outcomes.

What are the key steps and considerations for incorporating MCR-1 into virus-like particles?

Developing MCR-1-VLPs requires careful consideration of multiple factors:

Selection of VLP Platform:

• Consider capsid proteins from non-enveloped viruses that form robust VLPs (e.g., bacteriophage Qβ, MS2, or AP205)

• Evaluate compatibility with surface modifications and cargo loading

• Assess thermal and pH stability profiles for intended applications

Design Strategies for MCR-1 Incorporation:

Purification and Characterization:

• Isolate VLPs using density gradient ultracentrifugation or size-exclusion chromatography

• Verify structure using transmission electron microscopy and dynamic light scattering

• Confirm MCR-1 incorporation through immunoblotting, mass spectrometry, and functional assays

Drawing from chimeric VLP development approaches, researchers can adopt strategies similar to those used for GE11-modified MrNV VLPs, where peptides were incorporated at specific locations within the capsid structure .

How does the incorporation of MCR-1 affect VLP structure and stability?

The incorporation of MCR-1 into VLPs can significantly impact structural integrity and stability, requiring comprehensive analytical approaches to characterize these effects:

Structural Impact Assessment:

• Transmission electron microscopy (TEM) is essential for visualizing particle morphology and detecting structural alterations compared to unmodified VLPs

• Dynamic light scattering (DLS) measurements should be performed to evaluate size distribution and potential aggregation

• Circular dichroism (CD) spectroscopy can detect changes in secondary structure content

Stability Parameters to Monitor:

• Thermal stability through differential scanning calorimetry (DSC) or thermofluor assays

• pH stability across physiologically relevant ranges (pH 2-8)

• Storage stability at different temperatures and buffer conditions

• Resistance to proteolytic degradation

Research on modified VLPs demonstrates that strategic positioning of insertions is critical. As observed with chimeric MrNV VLPs containing EGFR-targeting peptides, modifications at certain locations preserved "the ability to form a mulberry-like VLP structure and to encapsulate EGFP DNA plasmid with an efficiency comparable to that previously reported for normal MrNV" . Similar principles should guide MCR-1-VLP development.

For advanced stability analysis, atomic force microscopy (AFM) can be employed to measure mechanical stiffness before and after modifications, similar to methods used for AP205 VLPs, where "heights distributions of AP205 VLP" and force versus indentation distance curves were analyzed to calculate stiffness parameters .

What assays can verify the enzymatic activity of MCR-1 in the context of VLPs?

Verifying MCR-1 enzymatic activity in the VLP context requires multi-faceted approaches:

In Vitro Enzymatic Assays:

• Phosphoethanolamine transfer activity using purified lipid A substrates

• Thin-layer chromatography (TLC) to visualize modified lipid products

• Mass spectrometry to detect and quantify PEA-modified lipid A species

• Colorimetric assays measuring phosphate release during the reaction

Functional Resistance Assessment:

• Minimum inhibitory concentration (MIC) assays with colistin using bacterial cells exposed to MCR-1-VLPs

• Time-kill kinetics to evaluate the dynamic protection against polymyxins

• Membrane permeability assays to assess functional modification of bacterial membranes

Structural Verification:

• Zn²⁺ binding assays to confirm metal coordination essential for catalysis

• Circular dichroism to verify proper folding of the MCR-1 component

• Protein-lipid interaction assays to confirm substrate binding capacity

Research has demonstrated that MCR-1 enzymatic activity correlates directly with colistin resistance levels, with MICs ranging from 1-8 μg/mL depending on expression levels. Studies using recombinant mcr-1-expressing E. coli showed that these strains had significantly different activation patterns of inflammatory pathways in human macrophage models compared to mcr-1-negative strains, suggesting functional activity affects host-pathogen interactions .

What is the current understanding of MCR-1's catalytic mechanism and active site requirements?

The catalytic mechanism of MCR-1 involves a zinc-dependent two-step process:

Step 1 (Rate-Limiting):

• Formation of a covalent phosphointermediate via phosphoethanolamine transfer from a membrane phospholipid donor to the acceptor Thr285

• Requires one Zn²⁺ ion for coordination but with limited direct involvement of Zn²⁺ orbitals in the reaction

Step 2:

• Transfer of the phosphoethanolamine group from Thr285 to lipid A

• Requires an additional Zn²⁺ ion that primarily functions to bind incoming lipid A and direct phosphoethanolamine addition

Deep mutational scanning of the MCR-1 active site has revealed critical residues essential for function:

• Zinc-chelating residues that maintain the catalytic metal center

• Residues forming a hydrogen bond network with the PEA moiety

• Hydrophobic residues that interact with acyl chains of phosphatidylethanolamine

Of 23 active-site residues analyzed through single-codon randomization libraries, 17 positions strongly preferred wild-type residues, indicating their crucial role in MCR-1 function. Mutations at these positions significantly decreased both polymyxin resistance levels and phosphoethanolamine transferase activity .

Computational studies using density functional theory (DFT) and ab initio calculations on cluster models have provided atomic-level insights into the transition states and energy barriers of these reactions, distinguishing MCR-1 from other phosphotransferases .

How does MCR-1 expression modulate bacterial immune evasion and host responses?

MCR-1 expression significantly alters host-pathogen interactions beyond simply conferring antibiotic resistance:

Inflammatory Pathway Modulation:

• Infection with mcr-1-expressing E. coli significantly modulates p38-MAPK and Jun N-terminal protein kinase (JNK) activation

• Affects pNF-κB nuclear translocation in host immune cells

• Alters expression of proinflammatory cytokines including TNF-α, IL-12, and IL-1β

Specific Host Response Changes:

• Reduced caspase-1 activity in infected macrophages

• Decreased IL-1β secretion compared to mcr-1-negative strains

• Modified immune recognition profiles due to altered lipid A structure

These findings suggest MCR-1 confers not only antibiotic resistance but also provides immune evasion advantages, potentially explaining its successful dissemination. Studies using THP-1 cells as a human macrophage model demonstrated that the lipid A modifications caused by MCR-1 directly impact how bacterial cells are recognized and processed by the immune system .

Understanding these immunomodulatory effects is crucial when designing MCR-1-VLPs for vaccine or therapeutic applications, as they may influence both safety and efficacy profiles.

How can MCR-1-VLPs be utilized for antimicrobial resistance research and vaccine development?

MCR-1-VLPs offer versatile platforms for multiple research applications:

For Antimicrobial Resistance Research:

• Structure-function studies of colistin resistance mechanisms without requiring live resistant bacteria

• High-throughput screening platforms for identifying MCR-1 inhibitors

• Tools for studying MCR-1 variant evolution and horizontal gene transfer dynamics

• Models for understanding the relationship between lipid A modification and other resistance mechanisms

For Vaccine Development:

• Presentation of MCR-1 epitopes in their native conformation to generate neutralizing antibodies

• Development of immunization strategies targeting conserved regions across MCR variants

• Design of bivalent vaccines combining MCR-1 with other resistance determinants

Strategic Advantages:

• VLPs efficiently drain to lymph nodes and stimulate both humoral and cellular immunity

• They can "elicit efficient protective immunity as direct immunogens compared to soluble antigens co-administered with adjuvants"

• Their particulate nature enhances uptake by dendritic cells and cross-presentation pathways

• Multiple antigens can be displayed on a single VLP platform

Research has demonstrated VLPs stimulate immunity through multiple mechanisms: activation of innate immunity via TLRs and pattern recognition receptors, induction of strong humoral responses (including T-cell independent IgM production), and enhanced antigen processing through both MHC I and MHC II pathways .

What are the technical challenges in studying different MCR variants using VLP technology?

Researching diverse MCR variants through VLP technology presents several technical challenges:

Variant-Specific Challenges:

• Heterogeneous distribution patterns of MCR variants across geographic regions and sources

• Variable expression levels and fitness costs associated with different variants

• Structural differences affecting incorporation into VLP platforms

• Variant-specific post-translational modifications and folding requirements

Technical Considerations:

Metagenomic studies analyzing 214,095 samples (442 Tbp of sequencing reads) revealed that "the dissemination of each variant is not uniform. Instead, the source and location play a role in the spread" . This heterogeneity must be considered when designing broadly reactive MCR-VLP constructs.

Additionally, evidence of new subvariants occurring in specific environments, such as a "highly prevalent and new variant of mcr-9," highlights the need for flexible VLP platforms that can be rapidly adapted to emerging variants .

What statistical approaches best analyze the relationship between MCR-1 expression levels and phenotypic outcomes?

Robust statistical frameworks are essential for analyzing how MCR-1 expression levels correlate with phenotypic outcomes:

Recommended Statistical Methods:

• Multivariate regression analysis to identify relationships between expression levels, resistance profiles, and growth parameters

• Principal component analysis (PCA) to reduce dimensionality in complex datasets

• Time-series analysis for growth and fitness experiments

• Hierarchical clustering to identify patterns across multiple parameters

• ANOVA with post-hoc tests to compare multiple expression conditions

Key Analytical Approaches:

• Dose-response modeling to quantify the relationship between MCR-1 expression and colistin MICs

• Survival analysis for time-to-resistance development

• Bayesian inference methods for systems with high variability

Research with chromosomal integration of mcr-1 under different promoters demonstrated a clear correlation: "The colistin MICs of the seven strains increased with the increase of MCR-1 levels, and the highest MIC was 8 μg/mL" . Studies have also shown that while lower expression levels had minimal effects on bacterial fitness, "higher tolerable expression of mcr-1 tended to show fitness costs in growth rate, competitive ability, and cell structures" .

These findings emphasize the importance of quantitative approaches that can capture both the direct resistance effects and the collateral consequences of MCR-1 expression.

How can researchers differentiate between MCR-1-mediated effects and other resistance mechanisms in experimental systems?

Distinguishing MCR-1-specific effects from other resistance mechanisms requires carefully designed control experiments and analytical techniques:

Experimental Controls:

• Isogenic strain pairs differing only in mcr-1 expression

• Site-directed mutagenesis of key catalytic residues to create enzymatically inactive MCR-1 controls

• Complementation studies with wild-type and mutant mcr-1 variants

• Chemical inhibition of MCR-1 activity with specific inhibitors

Analytical Approaches:

• Lipid A structural analysis by mass spectrometry to confirm phosphoethanolamine modification

• Transcriptomic analysis to identify MCR-1-dependent gene expression changes

• Membrane charge and permeability assays to quantify surface modifications

• Competitive fitness assays comparing mcr-1-positive and negative strains under various conditions

Deep mutational scanning approaches have identified 17 active-site residues critical for MCR-1 function, providing targets for creating control constructs with impaired activity. These include "Zn²⁺-chelating residues as well as residues that may form a hydrogen bond network with the PEA moiety or make hydrophobic interactions with the acyl chains of PE" .

For advanced mechanistic studies, researchers should consider probing the zinc dependency of observed phenotypes, as computational studies have demonstrated that while the first step of MCR-1 catalysis requires one Zn²⁺ ion, the second step requires an additional Zn²⁺ ion primarily involved in substrate binding .

What are the most promising approaches for developing inhibitors targeting MCR-1 in VLP-based delivery systems?

MCR-1 inhibitor development using VLP delivery platforms represents an innovative approach with several promising strategies:

Target-Based Design Strategies:

• Structure-based design focusing on the 17 critical active-site residues identified through deep mutational scanning

• Transition state analogs that mimic the covalent phosphointermediate formed at Thr285

• Zinc-chelating agents that can be selectively delivered to bacteria

• Phosphoethanolamine mimetics that compete with natural substrates

VLP-Specific Delivery Approaches:

• Encapsulation of small molecule inhibitors within VLPs for targeted bacterial delivery

• Display of peptide-based inhibitors on VLP surfaces

• Co-display of bacterial targeting ligands and inhibitor molecules

• Triggered release mechanisms activated in bacterial environments

Computational Screening Methodologies:

• Virtual screening against the complete two-step reaction mechanism identified through DFT calculations

• Molecular dynamics simulations to identify transient binding pockets

• Fragment-based approaches focused on the Zn²⁺ coordination environment

The understanding that MCR-1 catalysis proceeds through "a complete two-step reaction mechanism" with the "first step, formation of a covalent phosphointermediate via transfer of phosphoethanolamine from a membrane phospholipid donor to the acceptor Thr285, is rate-limiting" provides specific targets for inhibitor design. These mechanistic details "distinguish these enzymes from other phosphotransferases" and offer opportunities for selective inhibition .

How might environmental factors influence MCR-1-VLP stability and function in different research applications?

Environmental factors significantly impact MCR-1-VLP stability and function, requiring careful consideration in experimental design:

Critical Environmental Factors:

Application-Specific Considerations:

• For mucosal delivery: "VLPs are potentially interesting scaffolds for the oral or intranasal delivery of biomolecules, requiring stability in pH-varying environments"

• For long-term storage: Lyophilization protocols that preserve structure and function

• For in vivo studies: Assessment of serum stability and biodistribution

Recent research on surface cross-linking of VLPs demonstrates promising approaches to enhance stability: "Surface Cross-Linking by Macromolecular Tethers Enhances Virus-Like Particle Stability" . Similar strategies could be applied to MCR-1-VLPs to improve their robustness in various research applications, particularly for studies involving harsh environments or extended timelines.